Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A dual acting drug for enhancing radiotherapeutic benefit

Award Number: R43CA180316
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/19/2014
PERIOD OF PERFORMANCE END DATE: 03/18/2016

Group Awards By:

View Award Description

A dual acting drug for enhancing radiotherapeutic benefit - ABSTRACT: This proposal entitled "A dual acting drug for enhancing radiotherapeutic benefit" is designed to provide proof of concept evidence that the novel compound EWA001 can protect normal lung tissue from radiation-induced damage within an in vivo model without appreciably protecting neoplastic tissue. The protection of radiation induced lung toxicity from ionizing radiation and in particular, radiation induced pneumonitis and fibrosis, is an unmet need that may benefit thousands of patients considering that more than two thirds will receive radiation therapy during the course of their treatment for cancer with such complications limiting treatment or even resulting in death. In aim 1, we will examine the effect of EWA001 in tumor LLC and human tumor xenografts in vitro and in vivo in conjunction with radiation. In aim 2, we will investigate EWA001's efficacy at protecting against and mitigating radiation induced lung injury in mice. Currently, there is no drug available that would minimize radiation toxicity to normal tissue without interfering with its anti-tumor effect and this data is designed to lead to a successful phase II application where we will further develop the pre-clinical data towards an effective drug to treat radiation induced lung toxicity and pneumonitis.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2017 ( Subtotal = $0 )
2017	2014	BCN BIOSCIENCES L.L.C.	2265 E FOOTHILL BLVD	PASADENA	CA	91107	LOS ANGELES	USA	Cancer Treatment Research	000	1	10/24/2016	NEW	$0
														Subtotal = $0

Issue Date FY: 2014 ( Subtotal = $209,208 )
2014	2014	BCN BIOSCIENCES LLC	2275 EAST FOOTHILL BOULEVARD	PASADENA	CA	91107	LOS ANGELES	USA	Cancer Treatment Research	000	1	5/19/2014	NEW	$184,208
2014	2014	BCN BIOSCIENCES LLC	2275 EAST FOOTHILL BOULEVARD	PASADENA	CA	91107	LOS ANGELES	USA	Cancer Treatment Research	001	1	9/12/2014	NEW	$25,000
														Subtotal = $209,208

Grand Total All Awards = $209,208

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A dual acting drug for enhancing radiotherapeutic benefit

Award Number: R43CA180316

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/19/2014

PERIOD OF PERFORMANCE END DATE: 03/18/2016

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer